INTRODUCTION

To live longer, yet remain young and healthy, is one of the most ambitious dreams of humanity (1). At the beginning of the 20th century, according to the World Health Organization, the global average life expectancy was approximately 35 years. By the end of the century, the average human lifespan had almost doubled (2). This was mainly due to advances in science and technology leading to improved sanitary conditions, new therapies and drugs (such as antibiotics), new imaging methods (starting with the X-ray, which won the Nobel Prize in 1901), and the introduction of preventive medicine including vaccination campaigns and, later in the century, the promotion of healthy lifestyles (3,4).

Standing at the peak of healthcare evolution, one might wonder if this increase in life expectancy will continue. Moreover, within the current limits of the lifespan, we are already paying the price for living longer. Currently, we spend approximately 50% of the budget dedicated to healthcare on treating terminal illnesses such as cancer, heart failure, and other degenerative diseases (5,6). The single factor common to all of these diseases is aging. To better target the issues related to this increase in life expectancy, health care has changed since the decline in mortality caused by infectious diseases as well as chronic and non-contagious diseases, with a direct impact on the cost of public health and individual health care. We must now transition from traditional reactive medicine based on symptoms, diagnosis and treatment to a system that targets the disease before it occurs and, if it cannot be avoided, treats the disease in a personalized manner. Precision Medicine is that new way of thinking about medicine. In this paper, we performed a thorough review of the literature to present an updated review on the subject, discussing the impact of the use of genetics and genomics in the care process as well as medical education, clinical research and ethical issues. The Precision Medicine model is expanded upon in this article to include its principles of prediction, prevention, personalization and participation. Finally, we discuss Precision Medicine in various specialty fields and how it has been implemented in developing countries and its effects on public health and medical education.

KEYWORDS: Precision Medicine; Medical Education; Molecular Biology; Genetics; Genomics.

METHODS AND RESULTS

Illustrating the increasing popularity of “precision medicine”, a literature search of the PubMed/MEDLINE database conducted in March 2018 revealed 29,884 articles worldwide on the topic but only 241 when we added the “Brazil” filter. The number of articles has increased exponentially during the past decade (Figure 2), with half of these articles published in the last three years.

In addition, a meticulous search was performed for “precision medicine” in the PubMed/MEDLINE database from the same time period. Articles that referred to a specific disease or medical technique were excluded, as the authors agreed to focus on the precision medicine concept. Similar articles cited by the ones found in the initial search were also included. Those papers formed the database used to write a narrative literature review on the field.

DISCUSSION

The health disease process: from classical prevention theories to the 4 Ps

Reactive medicine is based on the principle of only treating diseases after their clinical initiation. This way of thinking...
has been found to be economically inferior to a model that acts before the beginning of symptoms in an effort to disrupt symptom development, which is known as Preventive Medicine (10).

Preventive medicine was clearly an important step for reducing the burdens of various diseases in populations. Preventive interventions focus on risk factors associated with a pathology - for instance, tabagism and the incidence of lung cancer - to generate a number needed to treat in order to prevent a disease event (10). In that sense, preventive medicine focuses on populations, whereas precision medicine includes tailored treatments and preventions.

We are rapidly approaching a point in healthcare evolution where it is possible to treat a disease while considering the

Figure 1 - The evolution of medicine. In the past, medicine was practiced according to the signs and symptoms presented by the patient and was solely based on the individual knowledge of the physician and thus was called intuition medicine. Currently, medicine is based on the evidence produced by scientific research, including clinical trials, which is designated as evidence-based medicine. In the future, medicine will be practiced according to algorithms that will take into consideration the patient’s characteristics, such as their genome, epigenetics, and lifestyle, constituting precision medicine.

Figure 2 - Graph showing the number of papers on “precision medicine” in the PubMed/MEDLINE database worldwide and the Brazilian contribution. *Articles until March 2018.
Changing the way we think about healthcare

Gameiro GR et al.

regarding the genome, microbiome, epigenome, exposome, and signs and symptoms of specific populations.

Implication of the 4 Ps theory in clinical research and its promotion in developing countries

Application of the precision medicine theory in developing countries is sometimes considered uncertain (14). In addition to the problem of financial support for the development of new therapies, the population of these countries remains without a sufficient amount of collected genomic data. For example, India has 20% of the global population but represents only 1% of existing genetic data (15). This representation problem also exists in genetic research. In genome-wide association studies (GWAS), 96% of the subjects studied were of European descent, which can result in findings that are less relevant for populations in developing countries (16).

Another challenge in developing countries is the gap between global health research funding and the health problems that affect populations from undeveloped and developing countries. According to the Global Forum for Health Research of 1999, only 10% of global funding goes to research on diseases that affect 90% of the world’s population (17). Furthermore, the number of publications in low- and middle-income countries is low; from 1990 until 2000, publications from all the countries of Latin America represented only 5.45% of the publications of the United States (18).

Precision medicine and medical education

Innovative ways to practice medicine will lead to redesigning the way in which we teach medicine. Medical education will need to shift the focus from pure content to the development of integrative skills and competences.

Gordon Moore, co-founder of Intel, postulated in 1965 that the number of transistors in a dense integrated circuit, and thus the processing capacity of computers, would double every 18 months. Scientific knowledge, particularly in the medical field, seems to be following a similar trend, primarily due to the computer revolution itself. This, although desirable, brings with it huge challenges to medical education, since no one person can follow all of the rapid and critical changes occurring in medicine every day. Therefore, medical students may often find themselves lost in a series of articles, textbooks, news stories, and editorials. However, it is crucial that they develop the ability to critically select information that is relevant for their education and apply this knowledge to solve the everyday challenges of various situations. However, basic subjects such as molecular and cell biology, genetics, and pathophysiology are more important than ever to understanding and practicing precision medicine.

Another competence of great importance to the medical education of the next era is interpersonal skills. Doctors are required, now more than ever, to be able to communicate and discuss treatment options not only with their patients but also with a series of other professionals with whom they must cooperate, both internally and externally in the healthcare sector. These other professionals include nurses, physiotherapists, speech therapists, and occupational therapists, as well as engineers and physicists, among others. It will also be beneficial for the next generation of doctors to understand, at least at a basic level, subjects that are not included in the current medical curriculum, such as coding,
artificial intelligence, blockchain technology, 3D printing and a series of other related topics.

Regarding how precision medicine could be taught to medical students, we believe that two main adjustments should be made to the current medical curriculum: first, learning of basic science subjects, focusing on how this knowledge can directly impact clinical practice, should be emphasized; second, it is of great importance to promote discussion panels on the evolution of medicine, bringing in experts in the groundbreaking fields that are changing healthcare and, thus, stimulating students to pursue a career on these areas. The University of Sao Paulo Medical School is developing new curricula that integrate basic and clinical sciences to include the skills required for the future of medicine.

Applications of precision medicine

What is already happening: The cases of oncology and psychiatry. Cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015 (19). Research examining the mechanisms involved in the pathogenesis of cancer, including the understanding of oncogenes and epigenetic clues in oncogenesis, has been performed continuously and at an increasing pace over the last several decades (20). Therefore, the discovery of potential targets for drug development - aiming to block the expression of those oncogenes by inactivating them or their pathways - is one of the promising aspects of precision medicine. One example of this concept, which is already being clinically applied, is the treatment of chronic myeloid leukemia (CML). Allogeneic bone-marrow transplants had long been considered the best treatment option, but they were indicated only for younger patients and continued to cause significant mortality (21). However, the discoveries of molecular predispositions that generate a variety of diseases, such as CML, made possible the development of more specific medications aimed at new molecular targets. Currently, the administration of a competitive inhibitor of the Bcr/Abl tyrosine kinase - an oncoprotein expressed in 95% of patients with CML and the molecular target for this disease - is able to achieve an 80% success rate of a complete cytogenetic response in newly diagnosed patients (22).

Among psychiatric illnesses, post-traumatic stress disorder (PTSD) is being extensively studied in the USA due its prevalence in soldiers returning from combat, which can reach 18.5% in this population according to data of Vietnam veterans (23). Animal research has already shown that in a stressful environment, epigenetic alterations in the hypothalamic-pituitary-adrenal axis can modulate the stress response (24). Other research has shown that combat veterans present an epigenetic alteration (hypomethylation) in the exon promoter region NR3C1-F1 of the glucocorticoid receptor gene, which could explain the changes in the neuroendocrine response of these soldiers (25). In contrast, the same exon NR3C1-F1 is the site of hypermethylation in suicide victims with a history of childhood abuse (26). These two subpopulations from different stress environments may be seen comparable if only the signs and symptoms are considered. The knowledge that these groups present opposing epigenetic modifications to the same gene makes it possible to approach treatment of these patients while taking into consideration their particular disease mechanisms and developing more efficient treatments for each group.

What is going to happen: Tissue engineering and regenerative medicine. Tissue engineering and regenerative medicine are fields that can make important contributions to developments in precision medicine. Among the innumerable possibilities within these research areas, there are two topics of interest: organs-on-a-chip and personalized stem cell therapies.

Organs-on-a-chip are 3D tissue-engineered platforms with microfluidic network systems that can be used to study the effect of virtually any substance on a specific tissue (27,28). This technology has gained great interest mainly due to the limitations inherent to the use of animal models during safety and efficacy testing, such as the poor translational potential and the ethical issues raised by animal experimentation (29). Although organs-on-a-chip have been increasingly utilized for preclinical testing of drugs, they present an even more interesting potential for use in precision medicine. The creation of patient-specific organs-on-a-chip would allow testing drug therapies in vitro before proceeding to the actual clinical treatment (30). Using induced pluripotent stem cells (iPSCs) from adult tissue, such as skin or blood, and differentiating them into any target tissue, from liver cells to neurons, it would be possible to create a patient-specific organ-on-a-chip to study how different drugs act on the patient’s own tissue and, based on this screening, to define a better therapeutic approach to treat a given disease, which can also be simulated in vitro (31-33). The New York Stem Cell Foundation (NYSCF) recently took an important step toward making personalized organs-on-a-chip closer to clinical application by creating a high-throughput robotic platform to automate the process of transforming patient samples into iPSCs and later into the target tissue cell types (34).

The final development of the organs-on-a-chip technology would be the creation of a whole body-on-a-chip, thus allowing the investigation of not only a drug’s efficacy on the targeted tissue but also its adverse effects on other tissues of the patient (35).

Personalized stem cell therapies, in turn, join the potential of regenerative medicine, which aims to replace or regenerate cells, tissues and organs, to the tailored approach used in precision medicine. While stem cell therapies are already, by default, a type of personalized therapeutic approach, since cell sources are, in most of the cases, autologous, methods exist to make these treatments even more personalized. The most interesting is the use of gene editing technologies to enhance stem cells or cure genetic disorders before the delivery of cells into the patient. Briefly, the process is characterized by isolating patient cells from any tissue, reprogramming them into iPSCs, modifying or correcting the cell genotype (or epigenetic factors) using technologies such as Zinc finger nucleases (ZFN), Transcription activator-like effector nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (36-37). The New York Stem Cell Foundation (NYSCF) recently took an important step toward making personalized organs-on-a-chip closer to clinical application by creating a high-throughput robotic platform to automate the process of transforming patient samples into iPSCs and later into the target tissue cell types (34).

The final development of the organs-on-a-chip technology would be the creation of a whole body-on-a-chip, thus allowing the investigation of not only a drug’s efficacy on the targeted tissue but also its adverse effects on other tissues of the patient (35).

Personalized stem cell therapies, in turn, join the potential of regenerative medicine, which aims to replace or regenerate cells, tissues and organs, to the tailored approach used in precision medicine. While stem cell therapies are already, by default, a type of personalized therapeutic approach, since cell sources are, in most of the cases, autologous, methods exist to make these treatments even more personalized. The most interesting is the use of gene editing technologies to enhance stem cells or cure genetic disorders before the delivery of cells into the patient. Briefly, the process is characterized by isolating patient cells from any tissue, reprogramming them into iPSCs, modifying or correcting the cell genotype (or epigenetic factors) using technologies such as Zinc finger nucleases (ZFN), Transcription activator-like effector nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (36-37). The New York Stem Cell Foundation (NYSCF) recently took an important step toward making personalized organs-on-a-chip closer to clinical application by creating a high-throughput robotic platform to automate the process of transforming patient samples into iPSCs and later into the target tissue cell types (34).

The final development of the organs-on-a-chip technology would be the creation of a whole body-on-a-chip, thus allowing the investigation of not only a drug’s efficacy on the targeted tissue but also its adverse effects on other tissues of the patient (35).

Personalized stem cell therapies, in turn, join the potential of regenerative medicine, which aims to replace or regenerate cells, tissues and organs, to the tailored approach used in precision medicine. While stem cell therapies are already, by default, a type of personalized therapeutic approach, since cell sources are, in most of the cases, autologous, methods exist to make these treatments even more personalized. The most interesting is the use of gene editing technologies to enhance stem cells or cure genetic disorders before the delivery of cells into the patient. Briefly, the process is characterized by isolating patient cells from any tissue, reprogramming them into iPSCs, modifying or correcting the cell genotype (or epigenetic factors) using technologies such as Zinc finger nucleases (ZFN), Transcription activator-like effector nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (36-37). The New York Stem Cell Foundation (NYSCF) recently took an important step toward making personalized organs-on-a-chip closer to clinical application by creating a high-throughput robotic platform to automate the process of transforming patient samples into iPSCs and later into the target tissue cell types (34).
Initiatives in precision medicine worldwide. The development of algorithms to predict and treat diseases based on a subpopulation-specific set of characteristics, such as genetics, drug responses, lifestyles, and social demands, requires a vast amount of information. Thus, instead of performing a series of separate and independent research protocols, initiatives aiming to create and integrate data from different medical centers are necessary. Using currently available tools, such as cloud computing, artificial intelligence, and big data, the collection and analysis of different databases will allow the creation of algorithms to direct clinical practice.

To contribute towards the development of precision medicine, the National Institutes of Health (NIH) announced, in 2015, the Precision Medicine Initiative (PMI), a program for delivering resources to projects aimed at creating new methods to improve healthcare by applying technologies that maximize effectiveness by taking into account individual variability in genes, environments, and lifestyles. The initiative focused not only on cutting-edge technologies but also on the interdisciplinary context of the research topics. Since then, researchers of various fields have been working together to break through this new frontier of medicine (45–47). The California Initiative to Advance Precision Medicine (CIAPM) is another initiative, launched in 2015, aiming to build a centralized information base. This initiative, a partnership among the University of California, the state of California and other entities, is expected to stimulate collaborations among clinicians, scientists, and patients to improve healthcare outcomes and foster innovations in the biomedical field.

One of the issues involved in building these large and centralized databases is related to consent, confidentiality and intellectual property. An immense ethical challenge exists in organizing these databases and giving access to different clinicians and researchers while protecting patient information from third party interests, as well as protecting the intellectual property of the scientist or clinician who collects the data.

Although the problem of limited genomic data from populations of developing countries is mainly due to the high costs, several startup companies are seeking to increase the amount of genomic data generated from Asian populations. The GenomeAsia 100K, a nonprofit consortium of companies and academics, wants to create reference genomes of all major Asian ethnic groups starting with the sequences of 100,000 people.

Finally, it is important to note that the significant advances in precision medicine produce concerns that must also be considered. Again, ethical issues are a critical problem, considering that all of the genetic, environmental, and lifestyle information of each patient will be stored in a database in the future. How should this information be kept safe and confidential? Taking this concept one step further, the possibility to genetically engineer patients and therefore create “super-humans” is not far away and fuels heated ethical debates. Considering this possibility, diseases will be able to be predicted, and we will also have the tools to prevent them before they occur; addressing this possibility is not something we are currently used to and is thus another skill we still need to develop.

AUTHOR CONTRIBUTIONS

GRG and VS contributed to the conception and design of the article, literature review, drafting the article, critical revision of the article and final approval of the version to be published. GRL contributed to the literature review, drafting the article, critical revision of the article and final approval of the version to be published. JOCA Jr. contributed to the conception and design of the article, critical revision of the article and final approval of the version to be published.

REFERENCES

1. Roser M. Life Expectancy. [Online] Available from: https://ourworldindata.org/life-expectancy
2. Riley J. Estimates of Regional and Global Life Expectancy, 1800–2001. Population and development review. 2005;31(3): 537–43, http://dx.doi.org/10.1111/j.1724-447X.2005.00083.x
3. Cutler D, Deaton A, Lleras-Muney A. The Determinants of Mortality. Journal of Economic Perspectives. 2006;20(3): 97–120, http://dx.doi.org/10.1257/jep.20.3.97
4. Oeppen J, Vaupel JW. Demography: Broken limits to life expectancy. Science. 2002;296(5570): 1029–31, http://dx.doi.org/10.1126.science.1069675
5. WHO Nutrition. [Online] WHO Nutrition. Available from: http://www.who.int/nutrition/topics/2_background/en/
6. Gareez-Leme LE, Leme MD. Costs of elderly health care in Brazil: chal- lenges and strategies. MedicalExpress. 2014;1(1): 3–8
7. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012;29(6): 613–24, http://dx.doi.org/10.1016/j.nbt.2012.03.004
8. Hood L. Health Care of the 21st Century: Predictive, Preventive, Personalized and Participatory (P4) Medicine. AAOMS. 2006;64(9): 14, http://dx.doi.org/10.1016/j.aaoms.2006.06.302
9. Galas DJ, Hood L. Systems Biology and Emerging Technologies Will Catalyze the Transition from Reactive Medicine to Predictive, Personalized, Preventive and Participatory (P4) Medicine. Interdisciplinary Bio Central. 2009;6(1): 1–4, http://dx.doi.org/10.4014/ibc.2009.2.006
10. Psaty BM, Dekkers OM, Cooper RS. Comparison of 2 Treatment Models: Precision Medicine and Preventive Medicine. JAMA. 2018; 320(8):751-2, http://dx.doi.org/10.1001/jama.2018.8377
11. Toledo RA, Sekiya T, Longuini VC, Coutinho FL, Lourenczo DM Jr, Toledo SP. Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil. Clinics. 2012;67(Suppl 1): 3–6, http://dx.doi.org/10.6061/clinics2012/67/S100102
12. Cass S. The age of the zettabyte Cisco: the future of internet traffic is video. IEEE Spectrum. 2014;51(3): 68, http://dx.doi.org/10.1109/MSPS. 2014.6745894
13. Committee on a Framework for Development a New Taxonomy of Disease, Board on Life Sciences, Division on Earth and Life Studies, National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. National Academies Press. 2011. 142 p.
14. Joly Y. Personnalized medicine in developing countries: a roadmap to personalization innovation. Current Pharmaceutogenomics and personalization medicine. 2011;9(3): 156–8, http://dx.doi.org/10.2174/1875921110905300156
15. Website. [Online] Available from: http://blogs.nature.com/businessreview/ 2018/01/10/sumit-jamuar-indians-are-20-of-the-worlds-population-but-represent-only-1-of-existing-genetic-data/
16. Bustamante CD, Burdug EK, De la Vega FM. Genomics for the world. Nature. 2011;475(7355): 163–5, http://dx.doi.org/10.1038/475163a.
17. Harris E. Building scientific capacity in developing countries. EMBIO Rep. 2004;5(1): 7–11, http://dx.doi.org/10.1038.sj.ejobs.7400058.
18. Hodana J, Albornoz M, Poluch EF, Poluch EF. El estado de la ciencia. Principales indicadores de ciencia y tecnologia Iberoamericanos/inter- americanos (RICYT). 2000. Revista Mexicana de Sociologia. 2002;64(2): 143.
19. WHO | Cancer. World Health Organization; 2018; Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed: 10th February 2018]
20. Fernandes GS, Marques DF, Giraldi DM, Braghiroli MIF, Coudry RA, Meireles SI, et al. Next-generation Sequencing-based genomic profiling: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 2016;164(5): 155–63, http://dx.doi.org/10.7326/101257-ep20.3.97
21. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beaty P, Bensinger WI, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 2016;164(5): 155–63, dx.doi.org/10.7326/101257-ep20.3.97
22. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7): 63, http://dx.doi.org/10.1182/blood-2004-08-309
23. Tanielian T, Jaycox LH. Invisible Wounds of War. Psychological and Cognitive Injuries, Their Consequences, and Services to Assist. RAND Corporation, 2008: 498 p.
24. Upreti BS, Sawo A. Environmental stressors and epigenetic control of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology. 2014;100(4): 278–87, http://dx.doi.org/10.1159/000369585.
25. Yehuda R, Flory JD, Bierer LM, Henrv-Haase C, Lehrner A, Desarnaud F, et al. Lower methylation of glucocorticoid receptor gene promoter in peripheral blood of veterans with posttraumatic stress disorder. Biol Psychiatry. 2015;77(4): 356–64, http://dx.doi.org/10.1016/j.biopsych. 2014.02.006.

26. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12(3): 342–8, http://dx.doi.org/10.1038/nn.2270.

27. Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190: 82–93, http://dx.doi.org/10.1016/j.jconrel. 2014.05.004.

28. Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, et al. Micro-fabrication of human organs-on-chips. Nat Protoc. 2015;10(1): 2135–57, http://dx.doi.org/10.1038/nprot.2013.137.

29. Liguori GR, Jeronimus BF, de Aquinas Liguori TT, Moreira LFP, Harmsen MC. Ethical Issues in the Use of Animal Models for Tissue Engineering: Reflections on Legal Aspects, Moral Theory, Three Rs Strategies, and Harm-Benefit Analysis. Tissue Eng Part C Methods. 2017;23(12): 3471–82, http://dx.doi.org/10.1089/ten.tec.2017.0189.

30. Williamson A, Singh S, Ferenkom U, Schuber A. The future of the patient-specific Body-on-a-chip. Lab Chip. 2013;13(18): 3471–80, http://dx.doi.org/10.1039/c3lc50237i.

31. Yum K, Hong SC, Healy KE, Lee LP. Physiologically relevant organs on chips. Biotechnol J. 2014;9(1): 16–27, http://dx.doi.org/10.1002/biot.201300187.

32. Mack DL, Guan X, Wagoner A, Walker SJ, Childers MK. Disease-in-a-dish: the contribution of patient-specific induced pluripotent stem cell technology to regenerative rehabilitation. Am J Phys Med Rehabil. 2014; 93(Suppl 3):S155–68, http://dx.doi.org/10.1097/PHM.000000000000141.

33. Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH, et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods. 2016;13(2): 151–7, http://dx.doi.org/10.1038/nmeth.3697.

34. Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods. 2015;12(9): 885–92, http://dx.doi.org/10.1038/nmeth.3307.

35. Kamei KI, Kato Y, Hiraiz Y, Ito S, Satoh J, Oka A, et al. Integrated heart/cancer on a chip to reproduce the side effects of anti-cancer drugs in vitro. RSC. advances. 2017;7(58): 36777–86, http://dx.doi.org/10.1039/C7RA07716E.

36. Garate Z, Davis BR, Quintana-Bustamante O, Segovia JC. New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum Gene Ther. 2013;24(6): 571–83, http://dx.doi.org/10.1089/hum.2012.251.

37. Hotta A, Yamanaka S. From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. Annu Rev Genet. 2015;49:47–70, http://dx.doi.org/10.1146/annurev-genet-112414-054926.

38. Vanhee S, Vandekerckhove B. Pluripotent stem cell based gene therapy for hematological diseases. Crit Rev Oncol Hematol. 2016;97: 238–46, http://dx.doi.org/10.1016/j.critrevonc.2015.08.022.

39. Srivastava A, Shahi RV. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102(2): 214–23, http://dx.doi.org/10.3334/haematol.2015.141200.

40. Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood. 2015;125(17): 2597–604, http://dx.doi.org/10.1182/blood-2015-12-613948.

41. Ma N, Liao B, Zhang H, Wang L, Shan Y, Xue Y, et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells. J Biol Chem. 2013;288(38): 34671–9, http://dx.doi.org/10.1074/jbc.M113.496174.

42. Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9): 1526–33, http://dx.doi.org/10.1101/gr.173427.114.

43. Ma N, Shan Y, Liao B, Kong G, Wang C, Huang K, et al. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs). J Biol Chem. 2015;290(19): 12079–89, http://dx.doi.org/10.1074/jbc.M114.624999.

44. Song B, Fan Y, He W, Zhu D, Niu X, Wang D, et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev. 2015;24(9): 1053–65, http://dx.doi.org/10.1089/scd.2014.0347.

45. Steenhuyzen J. NIH director sees solving data puzzle as key to U.S. precision medicine. Reuters. 2015. Available from: https://www.reuters.com/article/us-usa-health-precision/nih-director-sees-solving-data-puzzle-as-key-to-u-s-precision-medicine-idUSKBN0M302520150307

46. [No authors listed]. Advancing the Precision Medicine Initiative. Cancer Discov. 2015;5(12):1230.

47. Patil DJ, Devaney S. Precision Medicine: A One-Year Update. Medium. Available from: https://medium.com/@ObamaWhiteHouse/precision-medicine-a-one-year-update-a8b57a00e398 [Accessed: 6th March 2018]